The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures
Open accessAbstract
Differentiated HepaRG cells maintain liver-specific functions such as drug-metabolizing enzymes. In this study, the feasibility of HepaRG cells as a human hepatocyte model for in vitro toxicity assessment was examined using selected hepatotoxic compounds. First, basal drug-metabolizing enzyme activities (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, uridine 5'-diphospho-glucuronosyltransferase [UGT], and sulfotransferases [SULT]) were measured in HepaRG, human hepatocytes, and HepG2 cells. Enzyme activities in differentiated HepaRG cells were comparable to those in human hepatocytes and much higher than those in HepG2 cells, except for SULT activity. Second, we examined the cytotoxicity of hepatotoxic compounds, acetaminophen (APAP), aflatoxin B1 (AFB1), cyclophosphamide (CPA), tamoxifen (TAM), and troglitazone (TGZ) in HepaRG cells and human hepatocytes. AFB1- and CPA-induced cytotoxicities against HepaRG cells were comparable to those against human hepatocytes. Furthermore, the cytotoxicities of these compounds were inhibited by 1-aminobenzotriazole (ABT), a broad CYP inhibitor, in both cells and were likely mediated by metabolic activation by CYP. Finally, toxicogenomics analysis of HepG2 and HepaRG cells after exposure to AFB1 and CPA revealed that numerous p53-related genes were upregulated- and the expression of these genes was greater in HepaRG than in HepG2 cells. These results suggest that gene expression profiles of HepaRG cells were affected more considerably by the toxic mechanisms of AFB1 and CPA than the profiles of HepG2 cells were. Therefore, our investigation shows that HepaRG cells could be useful human hepatic cellular models for toxicity studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Primary (cryopreserved) human hepatocytes (PHHs) are the best in vitro hepatocyte models in current drug discovery research.7,8)”
From Cryopreservation of Hepatocyte Organoid-Derived Cells Generated from Human iPS Cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Infection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Seyec, J. L., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., TREPO, C. G., & Guguen‐Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,288
Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., & Guguen‐Guillouzo, C. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.003 · Cited by 714
Aninat, C., Piton, A., Glaise, D., Charpentier, T. L., Langouët, S., Morel, F., Guguen‐Guillouzo, C., & Guillouzo, A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006759 · Cited by 708
Gerets, H. H. J., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., & Atienzar, F. A. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-011-9208-4 · Cited by 698
Westerink, W. M. A., & Schoonen, W. G. E. J. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.05.014 · Cited by 544
Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
Guengerich, F. P. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-062 · Cited by 397
Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies
Kanebratt, K. P., & Andersson, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020016 · Cited by 355
Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Roy, P., Yu, L. J., Crespi, C. L., & Waxman, D. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15302-0 · Cited by 321
Cited by
Sorted by citations
Items 101–160 of 160
Li, H., Wang, Y., Ma, Z.-C., Yunhang, G., Ling, S., Teng-Fei, C., Guang-Ping, Z., & Gao, Y. (2021) · Xenobiotica · doi:10.1080/00498254.2021.1918800 · Cited by 5
Comparative In Vitro Toxicology of Novel Cytoprotective Short-Chain Naphthoquinones
Feng, Z., Sedeeq, M., Daniel, A., Corban, M., Woolley, K. L., Condie, R., Azimi, I., Smith, J. A., & Gueven, N. (2020) · Pharmaceuticals · doi:10.3390/ph13080184 · Cited by 5
Joshi, P., Kang, S., Acharya, P., Siddhpura, D., & Lee, M. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105688 · Cited by 4
Gampfer, T. M., Wagmann, L., Pulver, B., Westphal, F., Flockerzi, V., & Meyer, M. R. (2022) · Toxicology · doi:10.1016/j.tox.2022.153258 · Cited by 4
Kondo, T., Suzuki, I., Chiba, T., & Tousen, Y. (2022) · Journal of Food Science · doi:10.1111/1750-3841.16410 · Cited by 4
Han, W., Ding, M., Liu, S., Chen, Y., & Duan, Z. (2019) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2019.1646371 · Cited by 4
Yan, J., Wang, J., Jian, F., Cui, X., Zhang, Y., Yang, X., Gao, Q., Ding, Z., 汤钊猷, Fan, J., et al. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70033 · Cited by 3
Maepa, W., Marakalala, M. J., & Ndlovu, H. (2024) · BIO-PROTOCOL · doi:10.21769/bioprotoc.5042 · Cited by 3
Zagorski, J. W., & Kaminski, N. E. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114584 · Cited by 3
A turn-on fluorescent probe for imaging of hydroxyl radicals in drug-induced liver injury
Yu, M., Xiang, H., Taledaohan, A., Fu, W., Li, H., Wang, Y., & Xiao, N. (2024) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2024.125569 · Cited by 3
Comparative Analysis of Long Noncoding RNA Expression in Human Hepatocyte Cell Lines and Liver
Burenina, O. Y., Zatsepin, T. S., Kim, E. F., Владимирович, М. А., Skvortsov, D. A., Rubtsova, M. P., & Донцова, О. А. (2020) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672920040043 · Cited by 3
de Carvalho, V. S., Lima, K. M. M., de Azevedo, L. F. C., das Neves, P. A. P. F. G., Borges, R. S., Nagamachi, C. Y., & Pieczarka, J. C. (2022) · Toxicon · doi:10.1016/j.toxicon.2022.106940 · Cited by 3
Mizoi, K., Fukai, Y., Matsumoto, E., Koyama, S., Ishida, S., Kojima, H., & Ogihara, T. (2020) · Fundamental Toxicological Sciences · doi:10.2131/fts.7.9 · Cited by 3
Wu, L., Chen, S., Yang, Q., Li, X., Liu, L., Ji, S., Tang, S., Zhang, S., Wang, Y., Chen, R., et al. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.111934 · Cited by 2
Karaarslan, N., Yılmaz, İ., & Şirin, D. Y. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9578 · Cited by 2
Akiyama, S., Saku, N., Miyata, S., Ite, K., Nonaka, H., Toyoda, M., Kamiya, A., Kiyono, T., Kimura, T., Kasahara, M., et al. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.009 · Cited by 2
Horn, G., & Worek, F. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105811 · Cited by 2
Combination of biotransformation and metabolomics reveals tolfenpyrad-induced hepatocytotoxicity
Jiang, X. M., Zhu, Y., Dong, S., Lin, R., Zhu, P., Mao, J., Cao, Y., Yin, X., Dong, F., He, K., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.175320 · Cited by 2
Refining Hepatocyte Models to Capture the Impact of CYP2D6*10 Utilizing a PITCh System
Negoro, R., Ouchi, A., Deguchi, S., Takayama, K., & Fujita, T. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00202 · Cited by 2
Esteve-Turrillas, F. A., Trigueros-Sancho, A., Jover, R., Pérez-Guaita, D., & Quintás‐Cardama, A. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113908 · Cited by 2
Zhang, H., Hou, X., Liu, J., Su, J., Li, S., Chen, W., Guo, F., & Jiang, G. (2025) · Environment International · doi:10.1016/j.envint.2025.109848 · Cited by 2
Bioactivity Profiles of Cytoprotective Short-Chain Quinones
Feng, Z., Nadikudi, M., Woolley, K. L., Hemasa, A. L., Chear, S., Smith, J. A., & Gueven, N. (2021) · Molecules · doi:10.3390/molecules26051382 · Cited by 2
Horn, G., Demel, T., Rothmiller, S., Amend, N., & Worek, F. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2361879 · Cited by 2
Pawa, K., & Ray, S. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00159-7 · Cited by 2
Cryopreservation of Hepatocyte Organoid-Derived Cells Generated from Human iPS Cells
Nagai, W., Inui, J., Ueyama-Toba, Y., Asano, R., & Mizuguchi, H. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00276 · Cited by 1
In Vitro Assessment of Drug-Induced Liver Injury Using Cell-Based Models: A Review
Мазеркина, И. А. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-2-351 · Cited by 3
Mansouri, M., Lamichhane, A., Das, D., Aucejo, F., Tavana, H., & Leipzig, N. D. (2023) · Advanced Biology · doi:10.1002/adbi.202300386 · Cited by 1
Cell painting in HepaRG cells: an interlaboratory reproducibility study
Sherer, E. A., Chen, W., Aberasturi, D. T., Sagar, K., Li, Y., Sutake, Z., Xu, J., Harris, F. R., Harrill, J., & LaRocca, J. L. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf139 · Cited by 1
An alternative model for HEV infection in the HepaRG cell line
Gellenoncourt, S., Pellerin, M., Marcadet-Hauss, A., Fouillé, R., Rivoire, M. L., Passot, G., Lucifora, J., Durantel, D., Pavio, N., & Doceul, V. (2025) · Journal of Virological Methods · doi:10.1016/j.jviromet.2025.115307 · Cited by 1
Xu, G., Chen, Y., Jiang, S., Zhang, S., Ge, X., Zhang, F., & Gao, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1821870 · Cited by 1
Yamazaki, T., & Tokiwa, T. (2021) · Human Cell · doi:10.1007/s13577-021-00487-2 · Cited by 1
Structure‐dependent relative toxic potencies of selected pyrrolizidine alkaloids
Gao, L., & Schrenk, D. (2023) · Lebensmittelchemie · doi:10.1002/lemi.202352223 · Cited by 1
Jin, H.-J., Qiu, Z., Qian, C., Zhang, C.-Y., & Peng, Y. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115382 · Cited by 1
Kumaragurubaran, N., Yun, H. P., Zinovičius, A., Huang, S., Arul, P., Lin, H., Min-Shin, O., & Morkvėnaitė-Vilkončienė, I. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117538 · Cited by 1
Han, W., & Duan, Z. (2019) · Toxin Reviews · doi:10.1080/15569543.2019.1639060 · Cited by 1
Application and research progress of in vitro liver cancer cell culture models
Xing, J., Wang, Y., & Du, S. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i11.563 · Cited by 1
Shiohira, H., Fukunaga, K., Tayag, J. C. S., TAMASHIRO, Y., Mushiroda, T., & Nakamura, K. (2021) · Biomedical Research · doi:10.2220/biomedres.42.121 · Cited by 1
Filimonova, K., Rogovskaya, N. Y., Beltyukov, P. P., & Бабаков, В. Н. (2021) · Medicine of Extreme Situations · doi:10.47183/mes.2021.030 · Cited by 1
Joshi, P. (2019) · EngagedScholarship @ Cleveland State University (Cleveland State University)
Forchlorfenuron exposure Induces hepatocyte Apoptosis via MKK3/p38/ATF-2 signaling PathwayPreprint
Sun, X., Zhang, Y., Che, X., Dai, Z., Luo, Y., & Sun, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4212817/v1
Liver Systems in Safety Pharmacology
Mahajan, V. (2024) · Springer eBooks · doi:10.1007/978-3-030-73317-9_64-1
Liver Systems in Safety Pharmacology
Mahajan, V. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_64
Vos, K. D., Mols, R., Armoudjian, Y., Augustijns, P., & Annaert, P. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-03979-4
Laddha, A. P., Seyednejad, A., Donepudi, A. C., Goedken, M. J., Manautou, J. E., & Sartor, G. C. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111491
Early prediction of potential hepatotoxic metabolites to aid lead selection in drug discovery
Chiappalupi, L., Gargallo‐Viola, D., & Torrens, A. (2025) · Open Research Europe · doi:10.12688/openreseurope.21392.1
Li, Y., Wang, Q., Yang, Y., Huang, X., & Zhang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1666300
Sarfaraz, N., ROSEN, G. L., Winkler, T., Patel, R., Somarowthu, S., & Bouchard, M. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.30.685599
Takaoka, N., Morita, M., Takahashi, J., Esashika, K., Ohta, S., & Sanoh, S. (2026) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00489 · Cited by 1
Self-citationEffects of cyclophosphamide on the metabolism of primary mouse hepatocytes
Li, Y., Shi, J., Ju, W., & Zeng, L. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2026.2641207
Application of HepaRG mono- and HepaRG:THP-1 cocultures as immune responsive hepatotoxicity models
van Slobbe, G. J. J., Busch, M., Bakker, W., Govers, C., & Bouwmeester, H. (2026) · Toxicology · doi:10.1016/j.tox.2026.154466
Evaluation des mécanismes de cytotoxicité de molécules hautement énergétiques
Guyot, L. (2018) · theses.fr (ABES) · doi:10.70675/7e62e330z332az49d6zbf81z7256e3ee7c34
Xénobiotiques hépatotoxiques : études de métabolisme et mécanismes d’action
Daré, B. L. (2021) · theses.fr (ABES) · doi:10.70675/c23bbc49z8149z4490zaba3z80027345e9cc
Kroesen, M. D., Wagmann, L., Gehl, A.-L., Kiemer, A. K., & Meyer, M. R. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04444-6
Sfogliarini, C., Bernardinelli, C., Tran, L. H., Corsetto, P. A., Rizzo, A. M., Cattani, F., Cesta, M. C., Allegretti, M., Torre, S. D., Locati, M., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119708
A high-throughput screen to identify potential inhibitors of HSV-2
Hao, H., Roy, A., Johnson, D. K., & Davido, D. J. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106494
Human-Relevant 3D In Vitro Liver Spheroids for Preclinical Hepatotoxicity PredictionPreprint
Subia, B., Patel, H., Nathwani, S., Jain, M., & Viswanathan, K. (2026) · Research Square · doi:10.21203/rs.3.rs-10560086/v1
Nitaramorn, N., Kobpornchai, P., & Kulkeaw, K. (2026) · Methods · doi:10.1016/j.ymeth.2026.10.009
Lu, Z., Mao, T., Chai, L., Chen, K., Liu, K., Zhang, C., & Kou, H. (2026) · Phytotherapy Research · doi:10.1002/ptr.70493
Metadata
- Authors
- Yokoyama, Y., Sasaki, Y., Terasaki, N., Kawataki, T., Takekawa, K., Iwase, Y., Shimizu, T., Sanoh, S., & Ohta, S.
- Affiliations
- Hiroshima University (JP)
- Tanabe Pharma Corporation (Japan) (JP)
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2018-05-01
- Volume
- 41
- Issue
- 5
- Pages
- 722-732
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W2788132769
- Cited by
- 160
- References
- 37
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 23 · 2023: 16 · 2022: 17 · 2021: 23 · 2020: 37 · 2019: 8 · 2018: 5
- FWCI
- 20.08
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Biological and Pharmaceutical Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- HepaRG cells, cryopreserved human hepatocytes, HepG2 cells, drug metabolism, hepatotoxicity, drug-metabolizing enzymes, CYP enzymes, UGT, sulfotransferase, aflatoxin B1, cyclophosphamide, paracetamol, tamoxifen, troglitazone, 1-aminobenzotriazole, cytochrome P450 inhibition, cytotoxicity, toxicogenomics, in vitro toxicity testing
- MeSH terms
- Cell Line, Cells, Cultured, Cytochrome P-450 Enzyme System, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Glucuronosyltransferase, Sulfotransferases, Tumor Suppressor Protein p53, Toxicity Tests, Gene Expression Profiling, Hepatocytes, Hep G2 Cells, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
